BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 33866333)

  • 1. Response evaluation of bone metastasis in prostate cancer: Preliminary comparison of computerized bone scan index versus standardized clinical criteria.
    Petersen LJ; Gade M; Fonager RF; Albertsen S; Fledelius J; Ejlersen JA; Christensen MH; Aleksyniene R; Zacho HD
    Hell J Nucl Med; 2021; 24(1):2-9. PubMed ID: 33866333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate Cancer.
    Haupt F; Berding G; Namazian A; Wilke F; Böker A; Merseburger A; Geworski L; Kuczyk MA; Bengel FM; Peters I
    Adv Ther; 2017 Apr; 34(4):986-994. PubMed ID: 28265811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index.
    Imbriaco M; Larson SM; Yeung HW; Mawlawi OR; Erdi Y; Venkatraman ES; Scher HI
    Clin Cancer Res; 1998 Jul; 4(7):1765-72. PubMed ID: 9676853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.
    Ulmert D; Kaboteh R; Fox JJ; Savage C; Evans MJ; Lilja H; Abrahamsson PA; Björk T; Gerdtsson A; Bjartell A; Gjertsson P; Höglund P; Lomsky M; Ohlsson M; Richter J; Sadik M; Morris MJ; Scher HI; Sjöstrand K; Yu A; Suurküla M; Edenbrandt L; Larson SM
    Eur Urol; 2012 Jul; 62(1):78-84. PubMed ID: 22306323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Segmented linear correlations between bone scan index and prostate cancer biomarkers, alkaline phosphatase, and prostate specific antigen in patients with a Gleason score ≥7.
    Ebrahim T; Hadebe B; Aldous C; Tinarwo P; Nyakale N
    Medicine (Baltimore); 2022 Jun; 101(25):e29515. PubMed ID: 35758394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of computer-assisted analysis of skeletal lesions for the staging of prostate cancer.
    Petersen LJ; Mortensen JC; Bertelsen H; Zacho HD
    BMC Med Imaging; 2017 Jul; 17(1):40. PubMed ID: 28693433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.
    Anand A; Morris MJ; Kaboteh R; Båth L; Sadik M; Gjertsson P; Lomsky M; Edenbrandt L; Minarik D; Bjartell A
    J Nucl Med; 2016 Jan; 57(1):41-5. PubMed ID: 26315832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of bone scans in advanced prostate carcinoma using fully automated and semi-automated bone scan index methods.
    Takahashi Y; Yoshimura M; Suzuki K; Hashimoto T; Hirose H; Uchida K; Inoue S; Koizumi K; Tokuuye K
    Ann Nucl Med; 2012 Aug; 26(7):586-93. PubMed ID: 22744807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.
    Poulsen MH; Rasmussen J; Edenbrandt L; Høilund-Carlsen PF; Gerke O; Johansen A; Lund L
    BJU Int; 2016 May; 117(5):748-53. PubMed ID: 25906907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases.
    Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi J; Kondo K; Moriyama M; Takebayashi S; Yokomizo Y; Yao M; Uemura H; Noguchi K
    BMC Cancer; 2016 Feb; 16():128. PubMed ID: 26896160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
    Wakabayashi H; Nakajima K; Mizokami A; Namiki M; Inaki A; Taki J; Kinuya S
    Ann Nucl Med; 2013 Nov; 27(9):802-7. PubMed ID: 23828554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
    Dennis ER; Jia X; Mezheritskiy IS; Stephenson RD; Schoder H; Fox JJ; Heller G; Scher HI; Larson SM; Morris MJ
    J Clin Oncol; 2012 Feb; 30(5):519-24. PubMed ID: 22231045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study.
    Zacho HD; Gade M; Mortensen JC; Bertelsen H; Boldsen SK; Barsi T; Petersen LJ
    Urology; 2017 Oct; 108():135-141. PubMed ID: 28760556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective comparative study of
    Fonager RF; Zacho HD; Langkilde NC; Fledelius J; Ejlersen JA; Hendel HW; Haarmark C; Moe M; Mortensen JC; Jochumsen MR; Petersen LJ
    Acta Oncol; 2018 Aug; 57(8):1063-1069. PubMed ID: 29447047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI) study.
    Nakajima K; Kaneko G; Takahashi S; Matsuyama H; Shiina H; Ichikawa T; Horikoshi H; Hashine K; Sugiyama Y; Miyao T; Kamiyama M; Harada K; Ito A; Mizokami A;
    Int J Urol; 2018 May; 25(5):492-499. PubMed ID: 29633398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of bone metastatic burden by bone SPECT/CT in metastatic prostate cancer patients: defining threshold value for total bone uptake and assessment in radium-223 treated patients.
    Umeda T; Koizumi M; Fukai S; Miyaji N; Motegi K; Nakazawa S; Takiguchi T
    Ann Nucl Med; 2018 Feb; 32(2):105-113. PubMed ID: 29243019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study to evaluate the intra-individual reproducibility of bone scans for quantitative assessment in patients with metastatic prostate cancer.
    Reza M; Kaboteh R; Sadik M; Bjartell A; Wollmer P; Trägårdh E
    BMC Med Imaging; 2018 May; 18(1):8. PubMed ID: 29728144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer.
    Meirelles GS; Schöder H; Ravizzini GC; Gönen M; Fox JJ; Humm J; Morris MJ; Scher HI; Larson SM
    Clin Cancer Res; 2010 Dec; 16(24):6093-9. PubMed ID: 20975102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of the Usefulness of Bone Scan Index Calculated From 99m-Technetium- Hydroxymethylene Diphosphonate (
    Higashiyama S; Yoshida A; Kawabe J
    Curr Med Imaging; 2021; 17(1):89-96. PubMed ID: 32484112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.